At the time of writing, Myriad Genetics, Inc [MYGN] stock is trading at $14.56, down -0.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MYGN shares have gain 17.32% over the last week, with a monthly amount glided 10.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on February 12, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $29. Previously, UBS started tracking the stock with Neutral rating on December 10, 2024, and set its price target to $18. On December 09, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $21 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $32 on September 19, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $35 as its price target on August 28, 2024. Scotiabank started tracking with a Sector Outperform rating for this stock on June 27, 2024, and assigned it a price target of $29.
For the past year, the stock price of Myriad Genetics, Inc fluctuated between $12.04 and $29.30. Currently, Wall Street analysts expect the stock to reach $30.5 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $14.56 at the most recent close of the market. An investor can expect a potential return of 109.48% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
According to Myriad Genetics, Inc [NASDAQ:MYGN], the company’s sales were 823.60M for trailing twelve months, which represents an 11.15% jump. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.15 and Total Capital is -0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.34 points at the first support level, and at 14.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.88, and for the 2nd resistance point, it is at 15.20.
Ratios To Look Out For
It is important to note that Myriad Genetics, Inc [NASDAQ:MYGN] has a current ratio of 1.90. Also, the Quick Ratio is 1.73, while the Cash Ratio stands at 0.65. Considering the valuation of this stock, the price to sales ratio is 1.61, the price to book ratio is 1.81.
Transactions by insiders
Recent insider trading involved DIAZ PAUL J, President and CEO, that happened on Oct 11 ’24 when 15000.0 shares were sold. Officer, DIAZ PAUL J completed a deal on Oct 11 ’24 to buy 15000.0 shares. Meanwhile, Officer Ancona Margaret bought 11538.0 shares on Aug 21 ’24.
